Cholesterol retention in Alzheimer's brain is responsible for high β- and γ-secretase activities and Aβ production

Neurobiology of Disease

Volumn 29, Issue 3, 2008, Pages 422-437

  Xiong, Huaqi ^a,b   Callaghan, Debbie ^a   Jones, Aimee ^a   Walker, Douglas G ^c   Lue, Lih Fen ^c   Beach, Thomas G ^c   Sue, Lucia I ^c   Woulfe, John ^b   Xu, Huaxi ^d   Stanimirovic, Danica B ^a,b   Zhang, Wandong ^a,b  

^a NATIONAL RESEARCH COUNCIL CANADA   (Canada)

^b UNIVERSITY OF OTTAWA   (Canada)

^c SUN HEALTH RESEARCH INSTITUTE   (United States)

^d BURNHAM INSTITUTE   (United States)

Author keywords

and secretases; A production; Alzheimer's disease; Cholesterol retention; Nuclear receptors

Indexed keywords

APOLIPOPROTEIN E4; BETA SECRETASE; CELL NUCLEUS RECEPTOR; CHOLESTEROL; ERGOSTEROL; FILIPIN; GAMMA SECRETASE; HIGH DENSITY LIPOPROTEIN; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR; RETINOID X RECEPTOR; TRANSCRIPTION FACTOR;

AGED; ALLELE; ALZHEIMER DISEASE; ANIMAL CELL; ARTICLE; CELL CULTURE; CELL LYSATE; CHOLESTEROL METABOLISM; CONTROLLED STUDY; ENZYME ACTIVATION; ENZYME ACTIVITY; FEMALE; HOMEOSTASIS; HUMAN; HUMAN TISSUE; IN VITRO STUDY; MALE; MOUSE; NONHUMAN; PRIORITY JOURNAL; REAL TIME POLYMERASE CHAIN REACTION;

AGED; AGED, 80 AND OVER; ALZHEIMER DISEASE; AMYLOID BETA-PROTEIN; AMYLOID PRECURSOR PROTEIN SECRETASES; ANIMALS; BRAIN; CELL LINE, TUMOR; CELLS, CULTURED; CHOLESTEROL; ENZYME ACTIVATION; FEMALE; HUMANS; MALE; MICE;

EID: 39249084075     PISSN: 09699961     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.nbd.2007.10.005     Document Type: Article

References (63)

1. Abad-Rodriguez J., Ledesma M.D., Craessaerts K., Perga S., Medina M., Delacourte A., Dingwall C., De Strooper B., and Dotti C.G. Neuronal membrane cholesterol loss enhances amyloid peptide generation. J. Cell Biol. 167 5 (2004) 953-960
2. Abulrob A., Tauskela J.S., Mealing G., Brunette E., Faid K., and Stanimirovic D. Protection by cholesterol-extracting cyclodextrins: a role for N-methyl-d-aspartate receptor redistribution. J. Neurochem. 92 6 (2005) 1477-1486
3. Akiyama T.E., Sakai S., Lambert G., Nicol C.J., Matsusue K., Pimprale S., Lee Y.H., Ricote M., Glass C.K., Brewer Jr. H.B., and Gonzalez F.J. Conditional disruption of the peroxisome proliferator-activated receptor gamma gene in mice results in lowered expression of ABCA1, ABCG1, and apoE in macrophages and reduced cholesterol efflux. Mol. Cell. Biol. 22 8 (2002) 2607-2619
4. Bjorkhem I., and Meaney S. Brain cholesterol: long secret life behind a barrier. Arterioscler. Thromb. Vasc. Biol. 24 (2004) 806-815
5. Cordy J.M., Hooper N.M., and Turner A.J. Exclusively targeting beta-secretase to lipid rafts by GPI-anchor addition up-regulates beta-site processing of the amyloid precursor protein. Proc. Natl. Acad. Sci. U. S. A. 100 20 (2003) 11735-11740
6. Cordy J.M., Hooper N.M., and Turner A.J. The involvement of lipid rafts in Alzheimer's disease. Mol. Membr. Biol. 23 1 (2006) 111-122
7. Dermaut B., Theuns J., Sleegers K., Hasegawa H., Van den Broeck M., Vennekens K., Corsmit E., St George-Hyslop P., Cruts M., Van Duijn C.M., and Van Broeckhoven C. The gene encoding nicastrin, a major gamma-secretase component, modifies risk for familial early-onset Alzheimer disease in a Dutch population-based sample. Am. J. Hum. Genet. 70 6 (2002) 1568-1574
8. Dietschy J.M., and Turley S.D. Cholesterol metabolism in the brain. Curr. Opin. Lipidol. 12 (2001) 105-112
9. Edwards P.A., Kast H.R., and Anisfeld A.M. BAREing it all: the adoption of LXR and FXR and their roles in lipid homeostasis. J. Lipid Res. 43 (2002) 2-12
10. Ehehalt R., Keller P., Haass C., Thiele C., and Simons K. Amyloidogenic processing of the Alzheimer beta-amyloid precursor protein depends on lipid rafts. J. Cell Biol. 160 (2003) 113-123
11. Francis G.A., Fayard E., Picard F., and Auwerx J. Nuclear receptors and the control of metabolism. Annu. Rev. Physiol. 65 (2003) 261-311
12. Friedhoff L.T., Cullen E.I., Geoghagen N.S., and Buxbaum J.D. Treatment with controlled-release lovastatin decreases serum concentrations of human beta-amyloid (Abeta) peptide. Int. J. Neuropsychopharmacol. 4 2 (2001) 127-130
13. Fukumoto H., Deng A., Irizarry M.C., Fitzgerald M.L., and Rebeck G.W. Induction of the cholesterol transporter ABCA1 in central nervous system cells by liver X receptor agonists increases secreted Abeta levels. J. Biol. Chem. 277 50 (2002) 48508-48513
14. Hirsch-Reinshagen V., Zhou S., Burgess B.L., Bernier L., McIsaac S.A., Chan J.Y., Tansley G.H., Cohn J.S., Hayden M.R., and Wellington CL. Deficiency of ABCA1 impairs apolipoprotein E metabolism in brain. J. Biol. Chem. 279 (2004) 41197-41207
15. Hirsch-Reinshagen V., Maia L.F., Burgess B.L., Blain J.F., Naus K.E., McIsaac S.A., Parkinson P.F., Chan J.Y., Tansley G.H., Hayden M.R., Poirier J., Van Nostrand W., and Wellington C.L. The absence of ABCA1 decreases soluble apoE levels but does not diminish amyloid deposition in two murine models of Alzheimer's disease. J. Biol. Chem. 280 52 (2005) 43243-43256
16. Hixson J.E., and Vernier D.T. Restriction isotyping of human apolipoprotein E by gene amplification and cleavage with HhaI. J. Lipid Res. 31 3 (1990) 545-548
17. Howell W.M., and Brookes A.J. Evaluation of multiple presenilin 2 SNPs for association with early-onset sporadic Alzheimer disease. Am. J. Med. Genet. 111 2 (2002) 157-163
18. Huang Y. Molecular and cellular mechanisms of apolipoprotein E4 neurotoxicity and potential therapeutic strategies. Curr. Opin. Drug Discov. Dev. 9 5 (2006) 627-641
19. Johansson L., Rudling M., Scanlan T.S., Lundasen T., Webb P., Baxter J., Angelin B., and Parini P. Selective thyroid receptor modulation by GC-1 reduces serum lipids and stimulates steps of reverse cholesterol transport in euthyroid mice. Proc. Natl. Acad. Sci. U. S. A. 102 29 (2005) 10297-10302
20. Kaether C., and Haass C. A lipid boundary separates APP and secretases and limits amyloid beta-peptide generation. J. Cell Biol. 167 5 (2004) 809-812
21. Kalvodova L., Kahya N., Schwille P., Ehehalt R., Verkade P., Drechsel D., and Simons K. Lipids as modulators of proteolytic activity of BACE: involvement of cholesterol, glycosphingolipids, and anionic phospholipids in vitro. J. Biol. Chem. 280 44 (2005) 36815-36823
22. Katzov H., Chalmers K., Palmgren J., Andreasen N., Johansson B., Cairns N.J., Gatz M., Wilcock G.K., Love S., Pedersen N.L., Brookes A.J., Blennow K., Kehoe P.G., and Prince J.A. Genetic variants of ABCA1 modify Alzheimer disease risk and quantitative traits related to beta-amyloid metabolism. Hum. Mutat. 23 4 (2004) 358-367
23. Kinoshita A., Fukumoto H., Shah T., Whelan C.M., Irizarry MC., and Hyman B.T. Demonstration by FRET of BACE interaction with the amyloid precursor protein at the cell surface and in early endosomes. J. Cell Sci. 116 Pt 16 (2003) 3339-3346
24. Klopotek A., Hirche F., and Eder K. PPAR gamma ligand troglitazone lowers cholesterol synthesis in HepG2 and Caco-2 cells via a reduced concentration of nuclear SREBP-2. Exp. Biol. Med. ( Maywood ) 231 8 (2006) 1365-1372
25. Kojro E., Gimpl G., Lammich S., Marz W., and Fahrenholz F. Low cholesterol stimulates the nonamyloidogenic pathway by its effect on the alpha-secretase ADAM 10. Proc. Natl. Acad. Sci. U. S. A. 98 10 (2001) 5815-5820
26. Koldamova R.P., Lefterov I.M., Ikonomovic M.D., Skoko J., Lefterov P.I., Isanski B.A., DeKosky S.T., and Lazo J.S. 22R-hydroxycholesterol and 9-cis-retinoic acid induce ATP-binding cassette transporter A1 expression and cholesterol efflux in brain cells and decrease amyloid beta secretion. J. Biol. Chem. 278 15 (2003) 13244-13256
27. Koldamova R., Staufenbiel M., and Lefterov I. Lack of ABCA1 considerably decreases brain ApoE level and increases amyloid deposition in APP23 mice. J. Biol. Chem. 280 52 (2005) 43224-43235
28. Koldamova R.P., Lefterov I.M., Staufenbiel M., Wolfe D., Huang S., Glorioso J.C., Walter M., Roth M.G., and Lazo J.S. The liver X receptor ligand T0901317 decreases amyloid beta production in vitro and in a mouse model of Alzheimer's disease. J. Biol. Chem. 280 6 (2005) 4079-4088
29. Koudinov A.R., and Koudinova N.V. Essential role for cholesterol in synaptic plasticity and neural degeneration. FASEB J. 15 (2001) 1858-1860
30. Kraiem Z. Selective agonists and antagonists to thyroid hormone action. Thyroid 15 4 (2005) 336-339
31. Landreth G. PPARg agonists as new therapeutic agents for the treatment of Alzheimer's disease. Exp. Neurol. 199 2 (2006) 245-248
32. Abell L.L., Levy B.B., Brodie B.B., and Kendall F.E. A simplified method for the estimation of total cholesterol in serum and demonstration of its specificity. J. Biol. Chem. 195 (1952) 357-366
33. Miller L.J., and Chacko R. The role of cholesterol and statins in Alzheimer's disease. Ann. Pharmacother. 38 1 (2004) 91-98
34. Mojsilovic-Petrovic J., Nesic M., Pan A., Zhang W., and Stanimirovic D.B. Development of rapid staining protocols for laser capture microdissection of brain vessels from human and rat coupled to gene expression analyses. J. Neurosci. Methods 133 (2004) 39-48
35. Murthy S., Born E., Mathur S.N., and Field F.J. LXR/RXR activation enhances basolateral efflux of cholesterol in CaCo-2 cells. J. Lipid Res. 43 7 (2002) 1054-1564
36. Pfrieger F.W. Outsourcing in the brain: do neurons depend on cholesterol delivery by astrocytes?. BioEssays 25 1 (2003) 72-78
37. Preston S.D., Steart P.V., Wilkinson A., Nicoll J.A., and Weller R.O. Capillary and arterial cerebral amyloid angiopathy in Alzheimer's disease: defining the perivascular route for the elimination of amyloid beta from the human brain. Neuropathol. Appl. Neurobiol. 29 (2003) 106-117
38. Puglielli L., Tanzi R.E., and Kovacs D.M. Alzheimer's disease: the cholesterol connection. Nat. Neurosci. 6 4 (2005) 345-351
39. Refolo L.M., Malester B., LaFrancois J., Bryant-Thomas T., Wang R., Tint G.S., Sambamurti K., Duff K., and Pappolla M.A. Hypercholesterolemia accelerates the Alzheimer's amyloid pathology in a transgenic mouse model. Neurobiol. Dis. 7 4 (2000) 321-331
40. Refolo L.M., Pappolla M.A., LaFrancois J., Malester B., Schmidt S.D., Thomas-Bryant T., Tint G.S., Wang R., Mercken M., Petanceska S.S., and Duff K.E. A cholesterol-lowering drug reduces beta-amyloid pathology in a transgenic mouse model of Alzheimer's disease. Neurobiol. Dis. 8 5 (2001) 890-899
41. Schmitz G., and Langmann T. Transcriptional regulatory networks in lipid metabolism control ABCA1 expression. Biochim. Biophys. Acta 1735 1 (2005) 1-19
42. Selkoe D.J. Alzheimer disease: mechanistic understanding predicts novel therapies. Ann. Intern. Med. 140 8 (2004) 627-638
43. Simons M., Keller P., De Strooper B., Beyreuther K., Dotti C.G., and Simons K. Cholesterol depletion inhibits the generation of beta-amyloid in hippocampal neurons. Proc. Natl. Acad. Sci. U. S. A. 95 11 (1998) 6460-6464
44. Sjogren M., Gustafsson K., Syversen S., Olsson A., Edman A., Davidsson P., Wallin A., and Blennow K. Treatment with simvastatin in patients with Alzheimer's disease lowers both alpha- and beta-cleaved amyloid precursor protein. Dement. Geriatr. Cogn. Disord. 16 1 (2003) 25-30
45. Sun Y., Yao J., Kim T.W., and Tall A.R. Expression of liver X receptor target genes decreases cellular amyloid beta peptide secretion. J. Biol. Chem. 278 30 (2003) 27688-27694
46. Sundar P.D., Feingold E., Minster R.L., Dekosky S.T., and Kamboh M.I. Gender-specific association of ATP-binding cassette transporter 1 (ABCA1) polymorphisms with the risk of late-onset Alzheimer's disease. Neurobiol. Aging (2006) (May 22 Electronic publication ahead of print)
47. Tan Z.S., Seshadri S., Beiser A., Wilson P.W., Kiel D.P., Tocco M., D'Agostino R.B., and Wolf P.A. Plasma total cholesterol level as a risk factor for Alzheimer disease: the Framingham Study. Arch. Intern. Med. 163 9 (2003) 1053-1057
48. Wahrle S., Das P., Nyborg A.C., McLendon C., Shoji M., Kawarabayashi T., Younkin L.H., Younkin S.G., and Golde T.E. Cholesterol-dependent gamma-secretase activity in buoyant cholesterol-rich membrane microdomains. Neurobiol. Dis. 9 1 (2002) 11-23
49. Walter J., Kaether C., Steiner H., and Haass C. The cell biology of Alzheimer's disease: uncovering the secrets of secretases. Curr. Opin. Neurobiol. 11 5 (2001) 585-590
50. Wang N., Lan D., Chen W., Matsuura F., and Tall A.R. ATP-binding cassette transporters G1 and G4 mediate cellular cholesterol efflux to high-density lipoproteins. Proc. Natl. Acad. Sci. U. S. A. 101 26 (2004) 9774-9779
51. Webb P. Selective activators of thyroid hormone receptors. Expert Opin. Investig. Drugs 13 5 (2004) 489-500
52. Weller R.O., and Nicoll J.A. Cerebral amyloid angiopathy: pathogenesis and effects on aging and Alzheimer brain. Neurol. Res. 25 (2003) 611-616
53. Wiebe D.A., and Artiss J.D. Lipids, lipoproteins, and apolipoproteins. In: McClatchey K.D. (Ed). Clinical Laboratory Medicine (1994), Williams and Wilkins, Baltimore 287-302
54. Wollmer M.A., Streffer J.R., Lutjohann D., Tsolaki M., Iakovidou V., Hegi T., Pasch T., Jung H.H., Bergmann K., Nitsch R.M., Hock C., and Papassotiropoulos A. ABCA1 modulates CSF cholesterol levels and influences the age at onset of Alzheimer's disease. Neurobiol. Aging 24 3 (2003) 421-426
55. Wolozin B. A fluid connection: cholesterol and Aβ. Proc. Natl. Acad. Sci. U. S. A. 98 10 (2001) 5371-5373
56. Wolozin B. Cholesterol and the biology of Alzheimer's disease. Neuron 41 (2004) 7-10
57. Wolozin B., Kellman W., Ruosseau P., Celesia G.G., and Siegel G. Decreased prevalence of Alzheimer disease associated with 3-hydroxy-3-methyglutaryl coenzyme A reductase inhibitors. Arch. Neurol. 57 10 (2000) 1439-1443
58. Yasuda M., Hirono N., Maeda K., Imamura T., Mori E., and Tanaka C. Case-control study of presenilin-1 intronic polymorphism in sporadic early and late onset Alzheimer's disease. J. Neurol. Neurosurg. Psychiatry 66 6 (1999) 722-726
59. Ye S., Huang Y., Mullendorff K., Dong L., Giedt G., Meng E.C., Cohen F.E., Kuntz I.D., Weisgraber K.H., and Mahley R.W. Apolipoprotein (apo) E4 enhances amyloid beta peptide production in cultured neuronal cells: apoE structure as a potential therapeutic target. Proc. Natl. Acad. Sci. U. S. A. 102 51 (2005) 18700-18705
60. Zhang W., and Stanimirovic D.B. The transport systems of the blood-brain barrier. In: De Vries E., and Prat A. (Eds). The Blood-Brain Barrier and its Microenvironment: Basic Physiology to Neurological Disease (2005), Taylor & Francis Publisher Group, New York 103-142
61. Zhang W., Smith C., Shiparo A., Monette R., Hutchison J., and Stanimirovic D. Increased expression of bioactive chemokines in human cerebromicrovascular endothelial cells and astrocytes subjected to simulated ischemia in vitro. J. Neuroimmunol. 101 (1999) 148-160
62. Zhang W., Mojsilovic-Petrovic J., Andrade M., Zhang H., Ball M., and Stanimirovic D. Expression and functional characterization of ABCG2 in brain endothelial cells and vessels. FASEB J. 17 14 (2003) 2085-2087
63. Zhang W., Mojsilovic-Petrovic J., Callaghan D., Jones A., Cui H., Howlett C., and Stanimirovic D. Evidence that hypoxia-inducible factor-1 (HIF-1) mediates transcriptional activation of interleukin-1β (IL-1β) in astrocyte Cultures. J. Neuroimmunol. 174 (2006) 63-73